← Back to Home

Lyell plans $80 million private placement to support dual-target CAR-T toward a 2027 regulatory submission

Beyond clinical efficacy signals, the next stage for ronde-cel also requires continued funding. Lyell expects the private placement to extend its cash runway into 2028, covering key data releases and the planned submission timeline.

By SURL BioNews

Moving a cell therapy from clinical trials toward a regulatory submission requires not only efficacy data but also sufficient funding to sustain research and filing efforts. Lyell Immunopharma announced on November 4 that it had entered into an agreement for a private placement of approximately $80 million in common stock, expected to extend its cash runway into 2028 and support the pivotal trial and preparations for a U.S. regulatory submission for its dual-target CAR-T candidate, ronde-cel.

The significance of this financing is that the funds are expected to cover two important milestones: full pivotal trial data in mid-2027 and a planned biologics license application (BLA) submission to the U.S. Food and Drug Administration (FDA) in the second half of the same year. These remain company plans; securing funding can support execution, while trial results and the review timeline each carry their own uncertainties.

According to the company announcement and its 8-K filing, Lyell signed the agreement on November 3 and plans to issue 7,428,040 shares of common stock at $10.77 per share, with expected proceeds of approximately $80 million before expenses. The transaction was originally scheduled to close on or around November 4, subject to customary conditions. The filing also states that the company must file a registration statement for resale of the shares within 30 days after closing, and that failure to meet certain registration obligations will trigger cash penalties.

ronde-cel is being developed to treat relapsed or refractory large B-cell lymphoma and targets both CD19 and CD20. PiNACLE, which currently supports plans for the initial submission, is a single-arm trial in the third-line or later treatment setting. A separate Phase 3 randomized trial, PiNACLE-H2H, directly compares it with an investigator-selected, approved CD19 CAR-T therapy in the second-line setting. The two studies address different questions; the latter will help assess its performance relative to existing therapies.

The company expects to present additional PiNACLE data at the American Society of Hematology annual meeting in December 2026, followed by full pivotal data in mid-2027. RTTNews coverage of the financing and clinical update on the same day also reported the target of a submission in the second half of 2027. Proceeds from the financing will also support LYL273, a GCC-targeted CAR-T program for metastatic colorectal cancer, as well as operations and other uses; they will not be allocated entirely to ronde-cel.

For the development process, this private placement provides financial room through the data release and submission preparation period. Whether cash will last into 2028 as expected still depends on actual spending and research and development progress. Whether ronde-cel gains marketing approval will depend on regulatory review of the complete efficacy, safety and other application data.

References

  1. Lyell Immunopharma / GlobeNewswire
  2. Lyell Immunopharma, Inc. / SEC Form 8-K via StockTitan
  3. RTTNews